ClearSight Health:
SPOTLIGHT
Tue, Oct 11, 2022
3 minutes read
A hot topic of discussion at recent conferences has been the release of data from the Protected TAVR trial, which looked at Cerebral Embolic Protection (CEP) for Transcatheter Aortic Valve Replacement (TAVR).
Read More
Thu, Mar 04, 2021
Has COVID-19 pushed medical device sales reps out of the O.R. for good?
Thu, Jun 16, 2022
ClearSight Health at SIR
Thu, Jul 14, 2022
ClearSight Health Employee Spotlight: Rowan Cainer, VP of Growth
Thu, Sep 22, 2022
#TCT2022: Big changes on the horizon for treatment of the “silent killer” that affects nearly half of U.S. adults. Will the U.S. healthcare system be ready?
Tue, Oct 11, 2022
A bright future for risk reduction in TAVR procedures using CEP devices
Thu, Mar 04, 2021
Has COVID-19 pushed medical device sales reps out of the O.R. for good?
Thu, Jun 16, 2022
ClearSight Health at SIR
Thu, Jul 14, 2022
ClearSight Health Employee Spotlight: Rowan Cainer, VP of Growth
Thu, Sep 22, 2022
#TCT2022: Big changes on the horizon for treatment of the “silent killer” that affects nearly half of U.S. adults. Will the U.S. healthcare system be ready?
Tue, Oct 11, 2022
A bright future for risk reduction in TAVR procedures using CEP devices
